Acute kidney injury (AKI) is a sudden decrease in kidney function that develops within days and is detected by rising serum creatinine and/or reduced urine output. It is clinically important because it is common in hospitalized and critically ill patients and is associated with major complications.
Cadrenal Therapeutics received FDA guidance for a pivotal Phase 3 trial of CAD-1005 in HIT after an End-of-Phase 2 meeting. Phase 2 data showed a >25% absolute reduction in thrombotic events. The company also plans a Phase 2a trial in cardiac surgery-associated AKI.
Unicycive Therapeutics received an FDA Complete Response Letter for its oxylanthanum carbonate NDA resubmission due to third-party manufacturing deficiencies. The FDA raised no efficacy or safety concerns and requested no new data. Labeling discussions are ongoing.
Eledon Pharmaceuticals reported positive long-term Phase 2 BESTOW trial results for tegoprubart in kidney transplant, showing sustained kidney function benefits and improved patient outcomes versus tacrolimus. The company outlined plans for a Phase 3 registrational trial and seeks an FDA meeting in early 2027. Safety data indicated lower adverse event rates with tegoprubart.
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
Crohn’s disease is linked to kidney stones, dehydration and rare serious kidney complications. Monitoring, hydration and attention to medication-related risks can help protect kidney health.
A February 2026 review analyzes strategies for kidney-targeted drug delivery systems, examining renal targeting mechanisms and nanocarrier platforms. The review highlights how functionalized nanoparticles can achieve enhanced renal specificity while addressing remaining translational challenges in the field.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
The U.S. Food and Drug Administration has granted 510(k) clearance for Argos Infinity, Retia Medical's cardiovascular intelligence software platform designed for high-risk surgical and critical care environments across health systems.
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775482 |
Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial |
NOT_YET_RECRUITING | NA |
| NCT07765030 |
Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department |
NOT_YET_RECRUITING | |
| NCT07760129 |
Erector Spinae Oxygen Saturation and AKI After OPCAB |
NOT_YET_RECRUITING | |
| NCT07751913 |
ProNephro NGAL Test for Early Detection of Acute Kidney Injury in Adult ICU Patients (ALPACA) |
NOT_YET_RECRUITING | |
| NCT07751874 |
A Prospective, Observational Study to Evaluate the Safety and Feasibility of Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation in a Cohort Critical Ill Patients With Acute Kidney Injury and Presumed Absent Citrate Metabolism |
NOT_YET_RECRUITING | |
| NCT07751861 |
Metabolic Complications Using a Low- Versus High Concentration Citrate Solution for Regional Anticoagulation in Continuous Kidney Replacement Therapy: A Pragmatic Randomized Trial |
COMPLETED | NA |
| NCT07749417 |
Perioperative Transcutaneous Fluorescence Detection of GFR Trajectory for the Early Prediction and Diagnosis of CSA-AKI. |
RECRUITING | |
| NCT07746063 |
Body Composition, Kidney Size, and Medication Dosing in Acute Kidney Injury: Follow-Up at 90 Days and 12 Months |
COMPLETED | |
| NCT07743099 |
Renal and Cerebral NIRS and Early Acute Kidney Injury in Cooled Neonates With Birth Asphyxia |
COMPLETED | |
| NCT07739290 |
NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury |
NOT_YET_RECRUITING | NA |
